Mechanism of action study of anti-IL17 treatment in spondyloarthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling.

Trial Profile

Mechanism of action study of anti-IL17 treatment in spondyloarthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Spondylarthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Results published in the Arthritis and Rheumatology
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top